Other Viruses Citation List: May 23 - June 5, 2014
Hepatitis B Virus
1. Polyacetylenes and anti-Hepatitis B Virus Active Constituents from Artemisia capillaris. Zhao, Y., C.A. Geng, C.L. Sun, Y.B. Ma, X.Y. Huang, T.W. Cao, K. He, H. Wang, X.M. Zhang, and J.J. Chen. Fitoterapia, 2014. 95: p. 187-193; PMID[24685503].
[PubMed]. OV_0523-060514.
Hepatitis C Virus
2. The Combination of Alisporivir Plus an NS5A Inhibitor Provides Additive to Synergistic anti-Hepatitis C Virus Activity without Detectable Cross-resistance. Chatterji, U., J.A. Garcia-Rivera, J. Baugh, K. Gawlik, K.A. Wong, W. Zhong, C.A. Brass, N.V. Naoumov, and P.A. Gallay. Antimicrobial Agents and Chemotherapy, 2014. 58(6): p. 3327-3334; PMID[24687498].
[PubMed]. OV_0523-060514.
3. Identification of AP80978, a Novel Small-molecule Inhibitor of Hepatitis C Virus Replication That Targets NA4B. Dufner-Beattie, J., A. O'Guin, S. O'Guin, A. Briley, B. Wang, J. Balsarotti, R. Roth, G. Starkey, U. Slomczynska, A. Noueiry, P.D. Olivo, and C.M. Rice. Antimicrobial Agents and Chemotherapy, 2014. 58(6): p. 3399-3410; PMID[24709254].
[PubMed]. OV_0523-060514.
4. ABT-450/r-ombitasvir and Dasabuvir with or without Ribavirin for HCV. Ferenci, P., D. Bernstein, J. Lalezari, D. Cohen, Y. Luo, C. Cooper, E. Tam, R.T. Marinho, N. Tsai, A. Nyberg, T.D. Box, Z. Younes, P. Enayati, S. Green, Y. Baruch, B.R. Bhandari, F.A. Caruntu, T. Sepe, V. Chulanov, E. Janczewska, G. Rizzardini, J. Gervain, R. Planas, C. Moreno, T. Hassanein, W. Xie, M. King, T. Podsadecki, and K.R. Reddy. The New England Journal of Medicine, 2014. 370(21): p. 1983-1992; PMID[24795200].
[PubMed]. OV_0523-060514.
5. Preclinical Characterization of BMS-791325, an Allosteric Inhibitor of Hepatitis C Virus NS5B Polymerase. Lemm, J.A., M. Liu, R.G. Gentles, M. Ding, S. Voss, L.A. Pelosi, Y.K. Wang, K.L. Rigat, K.W. Mosure, J.A. Bender, J.O. Knipe, R. Colonno, N.A. Meanwell, J.F. Kadow, K.S. Santone, S.B. Roberts, and M. Gao. Antimicrobial Agents and Chemotherapy, 2014. 58(6): p. 3485-3495; PMID[24733465].
[PubMed]. OV_0523-060514.
6. Selective Inhibition of Hepatitis C Virus Infection by Hydroxyzine and Benztropine. Mingorance, L., M. Friesland, M. Coto-Llerena, S. Perez-Del-Pulgar, L. Boix, J.M. Lopez-Oliva, J. Bruix, X. Forns, and P. Gastaminza. Antimicrobial Agents and Chemotherapy, 2014. 58(6): p. 3451-3460; PMID[24709263].
[PubMed]. OV_0523-060514.
7. Inhibition of Hepatitis C Virus Infection by NS5A-Specific Aptamer. Yu, X., Y. Gao, B. Xue, X. Wang, D. Yang, Y. Qin, R. Yu, N. Liu, L. Xu, X. Fang, and H. Zhu. Antiviral Research, 2014. 106: p. 116-124; PMID[24713119].
[PubMed]. OV_0523-060514.
Herpes Simplex Virus 1
8. Inhibitors of Signal Peptide Peptidase (SPP) Affect HSV-1 Infectivity in Vitro and in Vivo. Allen, S.J., K.R. Mott, and H. Ghiasi. Experimental Eye Research, 2014. 123: p. 8-15; PMID[24768597].
[PubMed]. OV_0523-060514.
9. Phenolic Compounds from Origanum vulgare and Their Antioxidant and Antiviral Activities. Zhang, X.L., Y.S. Guo, C.H. Wang, G.Q. Li, J.J. Xu, H.Y. Chung, W.C. Ye, Y.L. Li, and G.C. Wang. Food Chemistry, 2014. 152: p. 300-306; PMID[24444941].
[PubMed]. OV_0523-060514.
Citations from the ISI Web of Knowledge Listings for O.V.
10. HCV GT2, GT3 and GT4 NS5B Polymerases Exhibit Increased Phenotypic Susceptibility to Ribavirin and a Nucleoside Polymerase Inhibitor. Anton, E.D., K. Strommen, S. Jauregui, M. Cheng, Y. Tan, A. Rivera, A. Newton, J. Larson, J.M. Whitcomb, C.J. Petropoulos, W. Huang, and J.D. Reeves. Antiviral Therapy, 2013. 18: p. A11-A11; ISI[000335229500007].
[WOS]. OV_0523-060514.
11. Synthesis of Carbohydrate Methyl phosphoramidates. Ashmus, R.A. and T.L. Lowary. Organic Letters, 2014. 16(9): p. 2518-2521; ISI[000335491000056].
[WOS]. OV_0523-060514.
12. In Vitro Efficacy and Resistance Profiling of Protease Inhibitors against a Novel HCV Genotype 3a Replicon. Chan, K., M. Yu, B. Peng, A. Corsa, A. Worth, R. Gong, S. Xu, X. Chen, T. Appleby, J. Taylor, W. Delaney, and G. Cheng. Antiviral Therapy, 2013. 18: p. A13-A13; ISI[000335229500009].
[WOS]. OV_0523-060514.
13. Biochemical Characterization of beta-D-2 '-C-Methyl-2,6-diaminopurine-ribonucleoside-5 '-triphosphate as a Potent Inhibitor of Hepatitis C Virus (HCV) Polymerase. Ehteshami, M., S. Amiralaei, J.R. Shelton, S. Tao, J.E. Suesserman, H.W. Zhang, L. Zhou, S.J. Coats, and R.F. Schinazi. Antiviral Therapy, 2013. 18: p. A10-A10; ISI[000335229500006].
[WOS]. OV_0523-060514.
14. Implications of Baseline Polymorphisms for Potential Resistance to NS3 Protease and NS5A Inhibitors in Hepatitis C Virus Genotypes 1a, 2b and 3a. Lindstrom, I., N. Palanisamy, M. Kjellin, A. Danielsson, K. Bondeson, and J. Lennerstrand. Antiviral Therapy, 2013. 18: p. A55-A55; ISI[000335229500049].
[WOS]. OV_0523-060514.
15. Enantioselective Synthesis of an HCV NS5A Antagonist. Mangion, I.K., C.Y. Chen, H.M. Li, P. Maligres, Y.G. Chen, M. Christensen, R. Cohen, I. Jeon, A. Klapars, S. Krska, H. Nguyen, R.A. Reamer, B.D. Sherry, and I. Zavialov. Organic Letters, 2014. 16(9): p. 2310-2313; ISI[000335491000004].
[WOS]. OV_0523-060514.
16. Beta-D-2 '-C-Me-2,6-diaminopurine ribonucleoside phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine- and Guanosine-5 '-triphosphate Forms. Schinazi, R.F., L. Zhou, H.W. Zhang, S. Tao, L. Bassit, T. Whitaker, T.R. McBrayer, M. Ehteshami, S. Amiralaei, M. Detorio, and S.J. Coats. Antiviral Therapy, 2013. 18: p. A57-A57; ISI[000335229500051].
[WOS]. OV_0523-060514.
17. Effect of Weak Acid Hypochlorous Solution on Selected Viruses and Bacteria of Laboratory Rodents. Taharaguchi, M., K. Takimoto, A. Zamoto-Niikura, and Y.K. Yamada. Experimental Animals, 2014. 63(2): p. 141-147; ISI[000335203800004].
[WOS]. OV_0523-060514.
18. Synthesis and Broad-spectrum Antiviral Activity of Some Novel Benzo-heterocyclic Amine Compounds. Zhang, D.J., W.F. Sun, Z.J. Zhong, R.M. Gao, H. Yi, Y.H. Li, Z.G. Peng, and Z.R. Li. Molecules, 2014. 19(1): p. 925-939; ISI[000334420300058].
[WOS]. OV_0523-060514.